Search Results - "Gross, Todd M"

ATX-101 for reduction of submental fat: A phase III randomized controlled trial by Humphrey, Shannon, MD, Sykes, Jonathan, MD, Kantor, Jonathan, MD, MSCE, MA, Bertucci, Vince, MD, Walker, Patricia, MD, PhD, Lee, Daniel R., MS, Lizzul, Paul F., MD, PhD, MPH, MBA, Gross, Todd M., PhD, Beddingfield, Frederick C., MD, PhD

“…Background ATX-101, an injectable form of deoxycholic acid, causes adipocytolysis when injected subcutaneously into fat. Objective We sought to evaluate the…”
Get full text

Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information by Dashtipour, Khashayar, Lee, Han S, Ellenbogen, Aaron, Kazerooni, Rashid, Gross, Todd M, Hollander, David A, Gallagher, Conor J

“…The first-line management of cervical dystonia (CD) symptoms is intramuscular injection of botulinum toxin type A (BoNTA). However, a comparison of safety…”
Get full text

Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A by Solish, Nowell, Carruthers, Jean, Kaufman, Joely, Rubio, Roman G., Gross, Todd M., Gallagher, Conor J.

“…Botulinum toxin type A (BoNTA) products are widely used for therapeutic and aesthetic indications, but there is a need for longer-lasting treatments that…”
Get full text

Clinical Benefits of DaxibotulinumtoxinA for Injection: Beyond Glabellar Line Effacement? by Mariwalla, Kavita, Shamban, Ava, Green, Jeremy B, Gross, Todd M, Brown, Jessica, Gallagher, Conor J

“…Botulinum toxin type A (BoNTA) is standard of care for glabellar lines ameliorization. DaxibotulinumtoxinA for Injection (DAXI) is a new BoNTA with a unique…”
Get full text

Lymph Node–Targeted Immunotherapy Mediates Potent Immunity Resulting in Regression of Isolated or Metastatic Human Papillomavirus–Transformed Tumors by SMITH, Kent A, MEISENBURG, Brenna L, CHIANG, Chih-Sheng, DA SILVA, Diane M, KÜNDIG, Thomas M, KAST, W. Martin, ZHIYONG QIU, BOT, Adrian, TAM, Victor L, PAGARIGAN, Robb R, WONG, Raymond, JOEA, Diljeet K, LANTZY, Liz, CARRILLO, Mayra A, GROSS, Todd M, MALYANKAR, Uriel M

“…Purpose: The goal of this study was to investigate the therapeutic potential of a novel immunotherapy strategy resulting in immunity to localized or metastatic…”
Get full text

Bridging the Gap: Sustained Treatment Effect of Glabellar Lines With Twice-A-Year Treatment With DaxibotulinumtoxinA by Dover, Jeffrey S., Solish, Nowell, Gross, Todd M., Gallagher, Conor J., Brown, Jessica

“…To achieve natural-looking outcomes when treating dynamic lines with botulinum toxin (BoNT), retreatment must be timed such that the patient maintains a…”
Get full text

REFINE-1, a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial With ATX-101, an Injectable Drug for Submental Fat Reduction by Jones, Derek H, Carruthers, Jean, Joseph, John H, Callender, Valerie D, Walker, Patricia, Lee, Daniel R, Subramanian, Meenakshi, Lizzul, Paul F, Gross, Todd M, Beddingfield, 3rd, Frederick C

“…ATX-101, an injectable form of deoxycholic acid, is approved in the United States and Canada for submental fat (SMF) reduction. To report results of REFINE-1,…”
Get full text

A randomized, double-blind, placebo-controlled trial of DaxibotulinumtoxinA for Injection for the treatment of upper limb spasticity in adults after stroke or traumatic brain injury by Patel, Atul T, Munin, Michael C, Ayyoub, Ziyad, Francisco, Gerard E, Kazerooni, Rashid, Gross, Todd M

“…Intramuscular injection of botulinum toxin type A is a first-line pharmacotherapy for adults with upper limb spasticity (ULS). However, reemergence of symptoms…”
Get full text

DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study by Fabi, Sabrina G., Cohen, Joel L., Green, Lawrence J., Dhawan, Sunil, Kontis, Theda C., Baumann, Leslie, Gross, Todd M., Gallagher, Conor J., Brown, Jessica, Rubio, Roman G.

“…BACKGROUNDDaxibotulinumtoxinA for Injection (DAXI) is botulinum toxin Type A formulated with a novel peptide excipient. Two pivotal, single-treatment,…”
Get full text

Overview of ATX-101 (Deoxycholic Acid Injection): A Nonsurgical Approach for Reduction of Submental Fat by Dayan, Steven H, Humphrey, Shannon, Jones, Derek H, Lizzul, Paul F, Gross, Todd M, Stauffer, Karen, Beddingfield, 3rd, Frederick C

“…In 2015, ATX-101 (deoxycholic acid injection; Kybella in the United States and Belkyra in Canada; Kythera Biopharmaceuticals, Inc., Westlake Village, CA [an…”
Get full text

Treatment of Upper Facial Lines With DaxibotulinumtoxinA for Injection: Results From an Open-Label Phase 2 Study by Dover, Jeffrey S., Humphrey, Shannon D., Lorenc, Z. Paul, Shamban, Ava, Gross, Todd M., Rubio, Roman G., Vitarella, Domenico

“…Simultaneous treatment of moderate-to-severe upper facial lines is reflective of real-world clinical practice. To evaluate the efficacy and safety of…”
Get full text

Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial by Comella, Cynthia L, Jankovic, Joseph, Hauser, Robert A, Patel, Atul T, Banach, Marta D, Ehler, Edvard, Vitarella, Domenico, Rubio, Roman G, Gross, Todd M

“…ASPEN-1 was a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, duration of response, and safety of 2 doses of…”
Get full text

Cohesive Polydensified Matrix Hyaluronic Acid for the Treatment of Etched-In Fine Facial Lines: A 6-Month, Open-Label Clinical Trial by Black, Jeanette M, Gross, Todd M, Murcia, Crystal L, Jones, Derek H

“…BACKGROUNDAvailable hyaluronic acid dermal fillers have unique biophysical properties that influence their clinical utility, longevity, and aesthetic outcomes…”
Get full text

Management of Patient Experience With ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental Fat by Dover, Jeffrey S, Kenkel, Jeffrey M, Carruthers, Alastair, Lizzul, Paul F, Gross, Todd M, Subramanian, Meenakshi, Beddingfield, 3rd, Frederick C

“…ATX-101 (deoxycholic acid injection; Kythera Biopharmaceuticals, Inc., Westlake Village, CA [an affiliate of Allergan plc, Dublin, Ireland]) was recently…”
Get full text

Efficacy and Safety of ATX-101 by Treatment Session: Pooled Analysis of Data From the Phase 3 REFINE Trials by Dayan, Steven H, Schlessinger, Joel, Beer, Kenneth, Donofrio, Lisa M, Jones, Derek H, Humphrey, Shannon, Carruthers, Jean, Lizzul, Paul F, Gross, Todd M, Beddingfield, Frederick C, Somogyi, Christine

“…Abstract Background ATX-101 (deoxycholic acid injection) is the only injectable drug approved for submental fat (SMF) reduction. In the phase 3 REFINE trials,…”
Get full text

LAP‐BAND® for Lower BMI: 2‐Year Results from the Multicenter Pivotal Study by Michaelson, Robert, Murphy, Diane K., Gross, Todd M., Whitcup, Scott M.

“…Objective The goal of this study was to examine the safety and effectiveness of the LAP‐BAND® System for patients with 30‐39.9 BMI and associated…”
Get full text

A bolus calculator is an effective means of controlling postprandial glycemia in patients on insulin pump therapy by Gross, Todd M, Kayne, David, King, Allen, Rother, Carla, Juth, Suzanne

“…Accurate bolus insulin doses require calculations based on (1) current blood glucose, (2) target blood glucose, (3) carbohydrate-to-insulin ratios, (4) total…”
Get more information

Performance evaluation of the MiniMed continuous glucose monitoring system during patient home use by Gross, T M, Bode, B W, Einhorn, D, Kayne, D M, Reed, J H, White, N H, Mastrototaro, J J

“…The recent availability of a continuous glucose monitor offers the opportunity to match the demands of intensive diabetes management with a period of equally…”
Get more information

Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study by Bode, Bruce W., Gross, Todd M., Thornton, Kay R., Mastrototaro, John J.

“…A 5-week pilot study was conducted to determine if continuous glucose monitoring could be used to improve glycemic control. A total of nine subjects with type…”
Get full text

Diabetes management in the new millennium using insulin pump therapy by Bode, Bruce W., Sabbah, Hassan T., Gross, Todd M., Fredrickson, Linda P., Davidson, Paul C.

“…Current goals of therapy of type 1 and 2 diabetes are to achieve near normal glycemia, minimize the risk of severe hypoglycemia, limit excessive weight gain,…”
Get full text